Describe Causes Of Upper Respiratory Infections And D 988928

Describe Causes Of Upper Respiratory Infections And Drug Therapydiscus

Describe causes of Upper respiratory infections and drug therapy Discuss triggers of asthma and treatment option Discuss corticosteroids Describe chronic bronchitis and treatment options Submission Instructions: Your initial post should be at least 500 words , formatted and cited in the current APA style with support from at least 2 academic sources. Each question must be answered individually as in bullet points.

Paper For Above instruction

Causes of Upper Respiratory Infections

Upper respiratory infections (URIs) are common illnesses that affect the nose, throat, and airways. These infections are predominantly caused by viruses, with the most prevalent being rhinoviruses, which are responsible for approximately 30-50% of URIs (Harber & Farrant, 2020). Adenoviruses, coronaviruses, and respiratory syncytial viruses (RSV) also contribute significantly to the incidence of URIs (Morris & Pondo, 2019). Bacterial pathogens, such as Streptococcus pyogenes, may sometimes cause secondary bacterial infections or be primarily responsible, particularly in cases of sinusitis or pharyngitis (Khan & Fatima, 2021). Environmental factors such as cold weather, humidity changes, and exposure to pollutants can predispose individuals to URIs by compromising mucosal defenses (Goyal et al., 2018). Additionally, lifestyle factors like smoking weaken respiratory defenses, increasing susceptibility (Perkins et al., 2022). The mode of transmission is primarily via respiratory droplets when infected individuals cough or sneeze, making close contact and crowded settings high-risk environments for infection spread (Chen et al., 2020).

Drug Therapy for Upper Respiratory Infections

Treatment of URIs is primarily supportive as most are viral and self-limiting. Symptomatic relief is the main focus, utilizing over-the-counter medications such as analgesics (acetaminophen or NSAIDs) to reduce fever and pain. Decongestants, including pseudoephedrine and topical nasal sprays, help alleviate nasal congestion (Smith & Lee, 2019). Antihistamines are employed mainly in cases with concomitant allergic symptoms. Antibiotics are generally not recommended unless bacterial superinfection is suspected, such as in confirmed bacterial sinusitis or streptococcal pharyngitis (Baker & Smith, 2021). The inappropriate use of antibiotics can contribute to antimicrobial resistance, making their judicious use imperative. Adjunct therapies include increased fluid intake, rest, and humidification of the air to ease breathing (Harper et al., 2020). Emerging evidence supports the use of nasal saline irrigations for symptom relief (Li et al., 2022). The role of antiviral medications is limited but may be considered in specific viral cases, such as influenza (Wong et al., 2021).

Triggers of Asthma and Treatment Options

Asthma triggers can be diverse and vary between individuals. Common environmental triggers include airborne allergens like pollen, dust mites, mold spores, pet dander, and air pollution particles (National Heart, Lung, and Blood Institute [NHLBI], 2022). Respiratory infections, notably viral infections such as the rhinovirus, also exacerbate asthma symptoms. Physical activity, cold air, and smoke are additional known triggers. Lifestyle factors such as stress and exposure to strong odors or chemicals can precipitate attacks (Reddel et al., 2017). Management involves avoiding known triggers and implementing pharmacological strategies. Long-term control is achieved with inhaled corticosteroids (ICS) and leukotriene receptor antagonists, which reduce airway inflammation. Rescue inhalers, typically short-acting beta-agonists like albuterol, provide rapid bronchodilation during acute exacerbations (Global Initiative for Asthma [GINA], 2023). Regular monitoring and individualized action plans are critical components of effective asthma management.

Corticosteroids in Asthma and COPD

Corticosteroids are cornerstone medications in the treatment of asthma and chronic obstructive pulmonary disease (COPD). In asthma, inhaled corticosteroids (ICS) such as fluticasone and budesonide are preferred for maintenance therapy, reducing airway inflammation, hyperresponsiveness, and frequency of exacerbations (Barnes, 2020). Systemic corticosteroids are reserved for severe exacerbations requiring rapid control of inflammation (Leung et al., 2021). In COPD, ICS combined with long-acting bronchodilators are used in patients with frequent exacerbations and significant airflow limitation (Vogelmeier et al., 2017). Corticosteroids exert their effects by modulating gene expression to suppress pro-inflammatory mediators, thus stabilizing airway structures (Barnes et al., 2019). Despite their efficacy, long-term use requires careful management to mitigate side effects like osteoporosis, adrenal suppression, and increased infection risk.

Chronic Bronchitis and Its Treatment Options

Chronic bronchitis is a form of COPD characterized by persistent inflammation of the bronchi, leading to increased mucus production and airflow obstruction. It is often caused by long-term exposure to cigarette smoke, occupational dust, and environmental pollutants (GOLD, 2022). The hallmark symptoms include a chronic productive cough lasting at least three months a year for two consecutive years (Rennard & Vestbo, 2019). Treatment aims to alleviate symptoms, prevent exacerbations, and improve quality of life. Pharmacologically, bronchodilators such as long-acting beta-agonists (LABAs) and anticholinergics are mainstays to open airways. Inhaled corticosteroids may be added if frequent exacerbations occur (GOLD, 2022). Pulmonary rehabilitation, smoking cessation, vaccination against influenza and pneumococcus, and oxygen therapy are essential components of comprehensive management. Emerging therapies focus on anti-inflammatory agents and biomarkers-targeted treatments (Vogelmeier et al., 2017). Recognizing early symptoms and encouraging lifestyle modifications remain vital in managing chronic bronchitis effectively.

References

  • Baker, R., & Smith, J. (2021). Antibiotic stewardship in upper respiratory infections. Journal of Infectious Diseases, 224(3), 453-459.
  • Barnes, P. J. (2020). Inhaled corticosteroids in asthma: Benefits and side effects. Respiratory Medicine, 165, 105-119.
  • Barnes, P. J., et al. (2019). Mechanisms of corticosteroid action in airway diseases. The Lancet, 394(10196), 702-713.
  • GOLD. (2022). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2022 Report). GOLD Reports.
  • Goyal, P., et al. (2018). Environmental risk factors for respiratory infections. Environmental Health Perspectives, 126(6), 067007.
  • Harber, P., & Farrant, J. (2020). Management of the common cold. American Journal of Medical Sciences, 359(2), 102-107.
  • Harper, D., et al. (2020). Supportive care in upper respiratory infections. Clinical Therapeutics, 42(1), 103-112.
  • Khan, S., & Fatima, S. (2021). Bacterial contributions to upper respiratory infections. Journal of Medical Microbiology, 70(4), 558-567.
  • Leung, C., et al. (2021). Systemic corticosteroids in acute asthma exacerbations. The New England Journal of Medicine, 385(10), 907-917.
  • Li, J., et al. (2022). Efficacy of saline nasal irrigation in treating upper respiratory symptoms. Cochrane Database of Systematic Reviews, (12), CD013927.
  • Morris, P., & Pondo, T. (2019). Viruses causing respiratory infections. Journal of Clinical Virology, 114, 1-7.
  • National Heart, Lung, and Blood Institute. (2022). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NHLBI.
  • Perkins, T., et al. (2022). Impact of smoking on respiratory illnesses. Tobacco Control, 31(2), 195-200.
  • Reddel, H. K., et al. (2017). Managing asthma triggers. Allergy, Asthma & Clinical Immunology, 13, 17.
  • Rennard, S. I., & Vestbo, J. (2019). Challenges in COPD management. Chest, 155(2), 400-406.
  • Smith, A., & Lee, M. (2019). Pharmacological management of upper respiratory symptoms. Pharmacology & Therapeutics, 205, 107413.
  • Vogelmeier, C., et al. (2017). Global strategy for the diagnosis, management, and prevention of COPD. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 195(5), 557-582.
  • Wong, C., et al. (2021). Antiviral treatments for influenza and respiratory viruses. Journal of Infectious Diseases, 224(Suppl 2), S122–S130.

Related Assignments